Global Head
Detlev Mennerich is the Global Head of the Boehringer Ingelheim Venture Fund since January 2025, following a distinguished 20-year career at Boehringer Ingelheim.
Detlev studied chemistry in Braunschweig and Bordeaux and holds a Ph.D. in Cell & Molecular Biology.
In 2001, Detlev began his industrial career at metaGen Pharmaceuticals and Schering AG in Berlin as a Scientist in Oncogenomics, focusing on target validation and biomarker research.
In 2005, he joined Boehringer Ingelheim in Biberach an der Riss, where he held several positions with increasing responsibility. He became Investment Director at the Boehringer Ingelheim Venture Fund in 2014, investing in clinical translation of pioneering therapeutic approaches, such as immuno-oncology, immuno-tolerization, and regenerative concepts. He served as a Board Member of ViraTherapeutics GmbH in Innsbruck and of NBE Therapeutics AG in Basel until their acquisition by Boehringer Ingelheim respectively in 2018 and 2021. In 2020, Detlev returned to the internal Discovery Research Unit as Global Head of Research Beyond Borders. By 2022, he took the role of Global Head of Business Development & Licensing for Boehringer Ingelheim.